...
首页> 外文期刊>Current Alzheimer Research rnCurrent Alzheimer Research >Editorial [Hot Topic: Alzheimer's Disease: Highlights from Research on Hormones, Growth Factors and Signaling Pathways (Debomoy K. Lahiri)]
【24h】

Editorial [Hot Topic: Alzheimer's Disease: Highlights from Research on Hormones, Growth Factors and Signaling Pathways (Debomoy K. Lahiri)]

机译:社论[热门话题:阿尔茨海默氏病:激素,生长因子和信号通路研究的重点(Debomoy K. Lahiri)]

获取原文
获取原文并翻译 | 示例
           

摘要

Current Alzheimer Research enters the fourth year of successful publication with a great sense of fulfilling our mission. During the last year, five issues of its third volume have been completed and published on time. The third volume featured a total of 65 articles in addition to Editorials.These articles, comprising primary research articles and review papers, were written and peer-reviewed by experts in neuroscience and Alzheimer's disease (AD). Current Alzheimer Research remains an international journal as exemplified by contributions from researchers belonging to 19 countries: Australia, Austria, Belgium, Canada, China, France, Germany, India, Israel, Italy, Japan, Netherlands, Singapore, Spain, Sri Lanka, Taiwan, UAE, UK and the USA. Diversity of the experimental models discussed in the last volume, which ranged from cell culture-based to animal and human studies is also worth noting. Success of the journal is reflected in its acceptance for listing in PubMed/MEDLINE and other databases. The journal is currently accessible via online (http://www.bentham.org/car/) and abstracts of each article are freely available on the journal's websitennThe focus of Current Alzheimer Research continues to be reporting mechanistic, drug-related and translational-based advances in Alzheimer's disease and related disorders. A wide range of topics in AD research, including amyloid biogenesis, brain imaging, immunotherapy, genetics, oxidative stress and tauopathy have been discussed by world renowned experts in the area, and several unique and controversial topics have been presented to encourage novel directions. In addition, the journal continues to publish results from clinical drug trials, including adequately-justified, evidencebased negative data. Covering the entire AD field is not an easy task, nor should it be our goal. For example, during the last single year alone, AD has captured over 3,800 citations on PubMED/MEDLINE search. Thus, the necessity of timely dissemination of this knowledge is of great importance. Although Current Alzheimer Research covers a small fraction of primary research, our review articles present a comprehensive overview of selected interesting topics, which makes an important contribution and provide a great resource to the AD field.nnIn the current fourth volume, with at least 5 different issues, Current Alzheimer Research gears up to present a wide range of themes in the forms of critical review articles and original research reports, which are expected to address the neurobiology of AD, analyze potential drug targets, and elucidate novel therapeutic strategies. The journal plans to cover research topics in current molecular, genetic, and in vivo models. Like previous years, the 4th volume will occasionally bring special issues written by experts on different “Hot Topics” of AD. Indeed, the next issue of the journal will be a special ‘ Hot Topic ’ issue entitled “Exploring the Links between Obesity and Alzheimer Research” (Guest Editor: Dr. Suzana Petanceska).nnIssue 1 of the 4th volume contains 8 articles, which address both the most interesting and relevant topics in the field of AD and neurodegenerative disorders and the potential utility of several valid targets for the therapy of AD. The present issue is focused on understanding signaling pathways, the role of different hormones and growth factors and the relevance of each in therapeutic strategies. However, the converging connection of these various factors to the amyloid pathway has not been overlooked in most instances. nnSeveral lines of evidence suggest that G protein-coupled receptors (GPCRs) play an important role in cellular signaling. Indeed, manipulation of transmembrane signaling by GPCRs is one of the most important therapeutic targets although, it has not been fully exploited in AD and other neurodegenerative diseases. Maudsley and colleagues (page 3-19) present a timely review on the complexity of G proteincoupled receptor signaling in neuronal tissue and its implications for novel therapeutics. The authors note that, with better understanding of the complexity of GPCR signaling, the rational design of ligands possessing increased specific efficacy and attenuated side effects should become the norm for drug development using this important and ubiquitous target. In the context of signaling, Aghdam and Barger discuss (page 21-31) the potential for therapeutic use of lithium in neuroprotective strategies and further elaborate both the hopes and caveats of this strategy.....
机译:当前的阿尔茨海默氏症研究已经进入成功出版的第四年,这极大地满足了我们的使命。去年,第三卷的五期已经完成并按时出版。第三卷除社论外,共有65篇文章,这些文章包括主要研究文章和评论论文,由神经科学和阿尔茨海默氏病(AD)专家撰写并经过同行评审。当前的阿尔茨海默病研究仍然是国际期刊,以下19个国家/地区的研究人员的贡献为例证:澳大利亚,奥地利,比利时,加拿大,中国,法国,德国,印度,以色列,意大利,日本,荷兰,新加坡,西班牙,斯里兰卡,台湾,阿联酋,英国和美国。在上一卷中讨论的实验模型的多样性也很值得注意,从基于细胞培养到动物和人类研究。该期刊的成功体现在对PubMed / MEDLINE和其他数据库的认可。该期刊目前可通过在线(http://www.bentham.org/car/)进行访问,并且每篇文章的摘要均可在该期刊的网站上免费获得。当前阿尔茨海默氏症研究的重点仍然是报告机理性,药物相关性和翻译性-阿尔茨海默氏病和相关疾病的研究进展。该领域的世界知名专家讨论了AD研究中的广泛主题,包括淀粉样生物发生,脑成像,免疫疗法,遗传学,氧化应激和tauopathy,并提出了一些独特且有争议的主题来鼓励新颖的方向。此外,该期刊继续发布临床药物试验的结果,包括充分合理的,基于证据的阴性数据。涵盖整个AD领域并非易事,也不是我们的目标。例如,仅在过去的一年中,AD就通过PubMED / MEDLINE搜索获得了3,800多次引用。因此,及时传播这种知识的必要性非常重要。尽管当前的阿尔茨海默氏病研究仅涉及一小部分基础研究,但我们的评论文章对选定的有趣主题进行了全面概述,这为AD领域做出了重要贡献并提供了巨大资源.nn在当前第四卷中,至少有5种不同的问题,当前的阿尔茨海默氏症研究正准备以严格的评论文章和原始研究报告的形式提出广泛的主题,这些主题有望解决AD的神经生物学问题,分析潜在的药物靶标并阐明新颖的治疗策略。该杂志计划涵盖当前分子,遗传和体内模型的研究主题。与往年一样,第四卷偶尔会带来由专家撰写的有关AD的不同“热门话题”的特殊问题。实际上,该杂志的下一期将是一个特别的“热门话题”,标题为“探索肥胖与阿尔茨海默病研究之间的联系”(来宾编辑:Suzana Petanceska博士)。nn第4卷第1期包含8篇文章,涉及AD和神经退行性疾病领域中最有趣,最相关的主题,以及几个有效靶点在AD治疗中的潜在效用。本期的重点是了解信号传导途径,不同激素和生长因子的作用以及每种激素在治疗策略中的相关性。然而,在大多数情况下,这些各种因素与淀粉样蛋白途径的融合联系并未被忽视。 nn有几条证据表明,G蛋白偶联受体(GPCR)在细胞信号传导中起重要作用。确实,尽管尚未在AD和其他神经退行性疾病中得到充分利用,但通过GPCR操纵跨膜信号是最重要的治疗靶标之一。 Maudsley及其同事(第3-19页)对神经元组织中G蛋白偶联受体信号传导的复杂性及其对新型疗法的意义进行了及时的综述。作者指出,通过更好地理解GPCR信号的复杂性,具有提高的特异性功效和减轻的副作用的配体的合理设计应成为使用这一重要且普遍存在的靶标进行药物开发的规范。在信号传导的背景下,Aghdam和Barger讨论了(第21-31页)锂在神经保护策略中的治疗用途,并进一步阐述了该策略的希望和警告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号